No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Mojo Vision Raises Additional $51 Million+ in Series B-1 Round

Funding to be Used for the Development of First True Smart Contact Lens

Editor: What To Know

  • Mojo Lens is a contact lens with a built-in display that is designed to give people useful and timely information without forcing them to look down at a screen or lose focus on the people and the world around them.
  • Mojo Vision, the Invisible Computing company, today announced it has raised more than $51 million in a Series B-1 investment round to propel the development of the first true smart contact lens, Mojo Lens.
  • This is a tremendously exciting opportunity and I'm humbled to be joining the board of directors and to continue partnering with the talented team at Mojo.

Mojo Vision, the Invisible Computing company, today announced it has raised more than $51 million in a Series B-1 investment round to propel the development of the first true smart contact lens, Mojo Lens.

This new round brings Mojo Vision’s total funding to date to more than $159 million.

Mojo Vision’s latest round of funding was led by New Enterprise Associates (NEA) with participation from top strategic investors and venture firms, including Gradient Ventures, Khosla Ventures, Liberty Global Ventures, Struck Capital, Dolby Family Ventures, Motorola Solutions Venture Capital, Fusion Fund, Intellectus Partners, KDDI Open Innovation Fund, Numbase Group, InFocus Capital Partners, and others.

Mojo also announced that Greg Papadopoulos, Ph.D., venture partner at NEA, will join its board of directors. Papadopoulos and NEA co-led the seed round in Mojo Vision along with CEO and co-founder Drew Perkins.

Papadopoulos has more than 30 years of experience in the technology industry and academia. Prior to NEA, Papadopoulos was EVP and CTO of Sun Microsystems and before Sun, he was an associate professor of EECS at the Massachusetts Institute of Technology (MIT). He has also helped found a number of companies and was an engineer with HP and Honeywell. Papadopoulos is a relentless advocate for diversity in engineering and a supporter of open development models that stimulate communication, inclusiveness, and innovation.

In January, Mojo announced that it is in the process of building the world’s first true smart contact lens, called Mojo Lens. Mojo Lens is a contact lens with a built-in display that is designed to give people useful and timely information without forcing them to look down at a screen or lose focus on the people and the world around them. Mojo calls this eyes-up experience Invisible Computing, a platform that enables information to be instantaneous, unobtrusive, and available hands-free, allowing people to interact with each other more freely and genuinely.

“The unveiling of the details of our product development earlier this year has generated increased excitement and momentum around the potential of Mojo Lens,” said Perkins. “This new round of funding brings more support and capital from strategic investors and companies to help us continue our breakthrough technology development. It gets us closer to bringing the benefits of Mojo Lens to people with vision impairments, to enterprises and eventually, consumers.”

The company is planning an early application of Mojo Lens to help people who live with vision impairment. By using enhanced image overlays, this application is designed to serve as a visual aid, providing real-time contrast and scene enhancement that will make navigation, obstacle avoidance, and personal interactions easier. Mojo is actively working with the U.S. Food and Drug Administration (FDA) through its Breakthrough Devices Program, a voluntary program designed to provide safe and timely access to medical devices that can help treat irreversibly debilitating diseases or conditions.

“NEA has been with Mojo since the beginning, sharing the vision to build and bring to market the first true smart contact lens,” said Papadopoulos. “The potential applications of this innovative technology could fundamentally change the way we work and view our world, as well as improve the quality of life for people with vision impairment. This is a tremendously exciting opportunity and I’m humbled to be joining the board of directors and to continue partnering with the talented team at Mojo.”

Mojo Lens is currently in the research and development phase and is not available for sale anywhere in the world.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy